Generex Biotechnology Corp (GNBT) Financial Statements (2024 and earlier)
Company Profile
Business Address |
10102 USA TODAY WAY MIRAMAR, FL 33025 |
State of Incorp. | DE |
Fiscal Year End | July 31 |
Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
4/30/2021 Q3 | 1/31/2021 Q2 | 10/31/2020 Q1 | 7/31/2020 Q4 | 4/30/2020 Q3 | 1/31/2020 Q2 | 10/31/2019 Q1 | |||
---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
Current Assets | |||||||||
Cash, cash equivalents, and short-term investments | 596 | 834 | 15 | 417 | 269 | 540 | |||
Cash and cash equivalents | 596 | 834 | 15 | 417 | 269 | 540 | |||
Inventory, net of allowances, customer advances and progress billings | 618 | 719 | 742 | 911 | 861 | 727 | |||
Inventory | 618 | 719 | 742 | 911 | 861 | 727 | |||
Other current assets | 389 | 307 | 332 | 624 | 504 | 451 | |||
Other undisclosed current assets | 169 | 184 | 165 | 142 | 240 | 155 | |||
Total current assets: | 1,773 | 2,043 | 1,255 | 2,093 | 1,874 | 1,873 | |||
Noncurrent Assets | |||||||||
Operating lease, right-of-use asset | 178 | 22 | 38 | 139 | 166 | 98 | |||
Property, plant and equipment | 145 | 176 | 214 | 245 | 483 | 532 | |||
Intangible assets, net (including goodwill) | 37,090 | 37,321 | 37,552 | 38,901 | 40,787 | 40,943 | |||
Goodwill | 34,489 | 34,489 | 34,489 | 38,901 | 38,901 | 38,901 | |||
Intangible assets, net (excluding goodwill) | 2,600 | 2,832 | 3,063 | 1,886 | 2,041 | ||||
Other undisclosed noncurrent assets | 6,324 | 6,324 | 6,324 | 10,517 | 8,793 | 8,795 | |||
Total noncurrent assets: | 43,737 | 43,842 | 44,128 | 49,802 | 50,229 | 50,367 | |||
TOTAL ASSETS: | 45,510 | 45,885 | 45,383 | 51,895 | 52,103 | 52,240 | |||
LIABILITIES AND EQUITY | |||||||||
Liabilities | |||||||||
Current Liabilities | |||||||||
Accounts payable and accrued liabilities, including: | 39,317 | 33,464 | 23,908 | 21,537 | 24,118 | 22,448 | |||
Interest and dividends payable | 3,911 | ||||||||
Employee-related liabilities | 7,060 | 7,005 | |||||||
Accounts payable | 1,316 | ||||||||
Other undisclosed accounts payable and accrued liabilities | 32,257 | 26,459 | 18,681 | 21,537 | 24,118 | 22,448 | |||
Deferred revenue | 3,000 | ||||||||
Debt | 10,057 | 9,981 | 11,166 | 12,145 | 11,907 | 1,026 | |||
Derivative instruments and hedges, liabilities | 1,317 | ||||||||
Due to related parties | 30 | 30 | |||||||
Other undisclosed current liabilities | 7,281 | 8,968 | 4,981 | 6,031 | 1,532 | 10,788 | |||
Total current liabilities: | 59,685 | 52,443 | 41,371 | 39,713 | 37,556 | 34,262 | |||
Noncurrent Liabilities | |||||||||
Long-term debt and lease obligation | 615 | 500 | 500 | 560 | 73 | 22 | |||
Long-term debt, excluding current maturities | 499 | 500 | 500 | 499 | |||||
Liabilities, other than long-term debt | 31,750 | 16,493 | 1,317 | 10,320 | 10,362 | 8,797 | |||
Operating lease, liability | 116 | 60 | 73 | 22 | |||||
Derivative instruments and hedges, liabilities | 31,750 | 16,493 | 1,317 | 10,320 | 10,362 | 8,797 | |||
Other undisclosed noncurrent liabilities | 8,572 | 8,483 | 10,079 | 187 | 88 | 216 | |||
Total noncurrent liabilities: | 40,937 | 25,476 | 11,896 | 11,067 | 10,523 | 9,035 | |||
Total liabilities: | 100,623 | 77,918 | 53,267 | 50,780 | 48,080 | 43,297 | |||
Temporary equity, carrying amount | 4,074 | 4,074 | 4,074 | 4,074 | 4,074 | 4,074 | |||
Equity | |||||||||
Equity, attributable to parent, including: | (59,187) | (36,107) | (11,958) | (2,959) | (51) | 4,869 | |||
Common stock | 113 | 108 | 82 | 80 | 69 | 44 | |||
Common stock, share subscribed but unissued, subscriptions receivable | (768) | (768) | |||||||
Additional paid in capital | 420,021 | 418,411 | 429,744 | 427,623 | 420,206 | 417,082 | |||
Accumulated other comprehensive income | 766 | 778 | 780 | 792 | 775 | 797 | |||
Accumulated deficit | (488,724) | (464,644) | (452,063) | (440,390) | (434,763) | (427,854) | |||
Stockholders' equity note, subscriptions receivable | (275) | ||||||||
Other undisclosed equity, attributable to parent | 8,913 | 9,239 | 9,498 | 9,703 | 14,430 | 14,800 | |||
Total equity: | (59,187) | (36,107) | (11,958) | (2,959) | (51) | 4,869 | |||
TOTAL LIABILITIES AND EQUITY: | 45,510 | 45,885 | 45,383 | 51,895 | 52,103 | 52,240 |
Income Statement (P&L) ($ in thousands)Annual | Quarterly
4/30/2021 Q3 | 1/31/2021 Q2 | 10/31/2020 Q1 | 7/31/2020 Q4 | 4/30/2020 Q3 | 1/31/2020 Q2 | 10/31/2019 Q1 | ||
---|---|---|---|---|---|---|---|---|
Revenues | 88 | (2,078) | 499 | 857 | 722 | |||
Cost of revenue | (105) | (23) | (164) | (116) | (166) | (134) | ||
Other undisclosed gross profit | 2,661 | |||||||
Gross profit: | (105) | 65 | 419 | 382 | 692 | 588 | ||
Operating expenses | (8,472) | (14,178) | (5,675) | (3,957) | (5,250) | (5,317) | ||
Other undisclosed operating income (loss) | (0) | 180 | ||||||
Operating loss: | (8,577) | (14,113) | (5,256) | (3,574) | (4,558) | (4,549) | ||
Interest and debt expense | (587) | (1,019) | (1,650) | (1,506) | (1,431) | (2,919) | ||
Loss from continuing operations: | (9,164) | (15,132) | (6,906) | (5,080) | (5,989) | (7,468) | ||
Loss before gain (loss) on sale of properties: | (9,164) | (15,132) | (6,906) | (5,080) | (5,989) | (7,468) | ||
Other undisclosed net income | ||||||||
Net income (loss): | (9,164) | (15,132) | (6,906) | (5,080) | (5,989) | (7,468) | ||
Net income attributable to noncontrolling interest | 326 | 258 | 206 | 134 | 371 | 187 | ||
Other undisclosed net income (loss) attributable to parent | (15,569) | 3,885 | (5,178) | (815) | (1,661) | (2,031) | ||
Net income (loss) attributable to parent: | (24,407) | (10,989) | (11,879) | (5,761) | (7,280) | (9,313) | ||
Other undisclosed net income available to common stockholders, basic | 326 | 258 | 206 | 134 | 371 | 187 | ||
Net income (loss) available to common stockholders, basic: | (24,081) | (10,731) | (11,673) | (5,626) | (6,910) | (9,126) | ||
Dilutive securities, effect on basic earnings per share | ||||||||
Other undisclosed net loss available to common stockholders, diluted | ||||||||
Net loss available to common stockholders, diluted: | (24,081) | (10,731) | (11,673) | (5,626) | (6,910) | (9,126) |
Comprehensive Income ($ in thousands)Annual | Quarterly
4/30/2021 Q3 | 1/31/2021 Q2 | 10/31/2020 Q1 | 7/31/2020 Q4 | 4/30/2020 Q3 | 1/31/2020 Q2 | 10/31/2019 Q1 | ||
---|---|---|---|---|---|---|---|---|
Net income (loss): | (9,164) | (15,132) | (6,906) | (5,080) | (5,989) | (7,468) | ||
Comprehensive income (loss): | (9,164) | (15,132) | (6,906) | (5,080) | (5,989) | (7,468) | ||
Comprehensive income, net of tax, attributable to noncontrolling interest | 326 | 258 | 206 | 134 | 371 | 187 | ||
Comprehensive income (loss), net of tax, attributable to parent: | (8,838) | (14,874) | (6,701) | (4,946) | (5,619) | (7,281) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.